Your weekly recap of news and analysis from the psychedelic sector.
Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data
This week: London-based Small Pharma’s DMT candidate fast-tracked by regulators; COMPASS secures fourth patent and shares group therapy data; Boris Johnson to consider rescheduling psilocybin; and more…
Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase to Psychedelics Production Quotas
This week: atai launches precision psychiatry company; DEA proposes further increases in psychedelics production quotas; TIME magazine covers psychedelics; and more…
Psychedelic Bulletin: Delix Raises $70m Series A; Toronto Gets Psychedelics Research Centre; Elon Musk Endorses Psychedelics
This week: Delix Therapeutics raises $70m to advance non-hallucinogenic psychedelics; Toronto gets a new psychedelics research centre thanks to $5m grant; Musk endorses psychedelics; and more…
Psychedelic Bulletin: Are REMS Patents the Next Frontier in the Psychedelics Patent Skirmish? Johns Hopkins Researcher Scores U.S. Government Grant
This week: we take a deep dive into REMS, which could be the next frontier of the psychedelics patent skirmish; Matthew W. Johnson receives grant from NIDA; and more…
Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics
This week: COMPASS Pathways acquires novel psychedelics and prodrugs IP portfolio; Wesana commits $1.5m to explore viability of joint venture with MAPS; Nine Perfect Strangers draws attention to psychedelic therapy; and more…
Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to Reduce Barriers to Schedule I Research
This week: four companies reveal further indications for psilocybin-related drug development efforts; Biden-Harris administration recommends parity between Schedule I and II research regulations; and more…